Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Helge L. Waldum, Gunnar Qvigstad, Reidar Fossmark, Per M. Kleveland & Arne K. Sandvik. (2010) Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scandinavian Journal of Gastroenterology 45:4, pages 389-394.
Read now
Read now
K. Kubo, A. Uehara, T. Kubota, T. Nozu, M. Moriya, Y. Watanabe, E. Shoji, S. B. Santos, K. Harada & Y. Kohgo. (1995) Effects of Ranitidine on Gastric Vesicles Containing H+, K+-Adenosine Triphosphatase in Rats. Scandinavian Journal of Gastroenterology 30:10, pages 944-951.
Read now
Read now
S. Teyssen, S. T. Chari, A. Joos & M. V. Singer. (1994) Effect of a 28-Day Therapy with Famotidine on Blood Levels of Alcohol and Gastrin and Intragastric pH in Healthy Human Subjects. Scandinavian Journal of Gastroenterology 29:5, pages 398-405.
Read now
Read now
I. N. Marks, J. A. Louw & G. O. Young. (1992) Acid Secretion, 1932-92: Advances, Adaptations, and Paradoxes. Scandinavian Journal of Gastroenterology 27:sup193, pages 7-13.
Read now
Read now
J. P. Miller & E. B. Faragher. (1989) The Potential Impact of Campylobacter pylori on the Treatment of Duodenal Ulcer Disease. Scandinavian Journal of Gastroenterology 24:sup160, pages 39-45.
Read now
Read now
J. P. Miller. (1989) Colloidal Bismuth in the Treatment of Duodenal Ulceration: The Benefit for the Patient. Scandinavian Journal of Gastroenterology 24:sup157, pages 16-20.
Read now
Read now
Articles from other publishers (32)
Marcus Zulian Teixeira. (2011) Rebound acid hypersecretion after withdrawal of gastric acid suppressing drugs: new evidence of similitude. Homeopathy 100:3, pages 148-156.
Crossref
Crossref
Anna Niklasson, Lina Lindström, Magnus Simrén, Greger Lindberg & Einar Björnsson. (2010) Dyspeptic Symptom Development After Discontinuation of a Proton Pump Inhibitor: A Double-Blind Placebo-Controlled Trial. American Journal of Gastroenterology 105:7, pages 1531-1537.
Crossref
Crossref
N. G. M. HUNFELD, W. P. GEUS & E. J. KUIPERS. (2006) Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors. Alimentary Pharmacology & Therapeutics 25:1, pages 39-46.
Crossref
Crossref
R. Fossmark, G. Johnsen, E. Johanessen & H. L. Waldum. (2005) Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Alimentary Pharmacology and Therapeutics 21:2, pages 149-154.
Crossref
Crossref
Gunnar Qvigstad & Helge Waldum. (2004) Rebound Hypersecretion after Inhibition of Gastric Acid Secretion. Basic & Clinical Pharmacology & Toxicology 94:5, pages 202-208.
Crossref
Crossref
Per G. Farup, P. H. Juul-Hansen & A. Rydning. (2001) Does Short-term Treatment With Proton Pump Inhibitors Cause Rebound Aggravation of Symptoms?. Journal of Clinical Gastroenterology 33:3, pages 206-209.
Crossref
Crossref
Derek Gillen & Kenneth E.L. McColl. (2001) Problems related to acid rebound and tachyphylaxis. Best Practice & Research Clinical Gastroenterology 15:3, pages 487-495.
Crossref
Crossref
D. Gillen & K. E. L. Mccoll. 2000. Helicobacter pylori. Helicobacter pylori
391
396
.
Derek Gillen, Angela A. Wirz, Joy E. Ardill & Kenneth E.L. McColl. (1999) Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 116:2, pages 239-247.
Crossref
Crossref
I. N. Marks & G. O. Young. 1995. Sucralfate. Sucralfate
191
196
.
P. DUROUX, C. EMDE, P. BAUERFEIND, J. BIOLLAZ, D. ARMSTRONG & A.‐L. BLUM. (2007) Early evening nizatidine intake with a meal optimizes the antisecretory effect. Alimentary Pharmacology & Therapeutics 7:1, pages 47-54.
Crossref
Crossref
A F Kummer, D A Johnston, I N Marks, G O Young, N A Tigler-Wybrandi & S A Bridger. (1992) Changes in nocturnal and peak acid outputs after duodenal ulcer healing with sucralfate or ranitidine.. Gut 33:2, pages 175-178.
Crossref
Crossref
C. H. Wilder-Smith, F. Halter & H. S. Merki. (1991) Tolerance and rebound to H2-receptor antagonists: Intragastric acidity in patients with duodenal ulcer. Digestive Diseases and Sciences 36:12, pages 1685-1690.
Crossref
Crossref
Martin J. Collen & Michael J. Sheridan. (1991) Definition for idiopathic gastric acid hypersecretion. Digestive Diseases and Sciences 36:10, pages 1371-1376.
Crossref
Crossref
G. M. FULLARTON, A. M. I. MACDONALD & K. E. L. McCOLL. (2007)
Rebound hypersecretion after H
2
‐antagonist withdrawal—a comparative study with nizatidine, ranitidine and famotidine
. Alimentary Pharmacology & Therapeutics 5:4, pages 391-398.
Crossref
Crossref
I.N. Marks, David A. Johnston & Gerardine O. Young. (1991) Acid secretory changes and early relapse following duodenal ulcer healing with ranitidine or sucralfate. The American Journal of Medicine 91:2, pages S95-S101.
Crossref
Crossref
David A. Johnston, I.N. Marks, Gerry O. Young, Nel A. Tigler-Wybrandi, Sharon Bridger & John Zak. (1991) Acid secretory responses and parietal cell sensitivity following duodenal ulcer healing with omeprazole, sucralfate, and maalox. The American Journal of Medicine 91:2, pages S91-S94.
Crossref
Crossref
J. W. Rademaker & R. H. Hunt. 1991. Pharmacology of Peptic Ulcer Disease. Pharmacology of Peptic Ulcer Disease
301
323
.
John A. Oates, Alastair J.J. Wood, Mark Feldman & Michael E. Burton. (1990)
Histamine
2
-Receptor Antagonists
. New England Journal of Medicine 323:24, pages 1672-1680.
Crossref
Crossref
D. A. JOHNSTON, I. N. MARKS, G. O. YOUNG, N. A. TIGLER-WYBRANDI & S. BRIDGER. (2007) Duodenal ulcer healing and acid secretory responses to modified sham feeding and pentagastrin stimulation. Alimentary Pharmacology & Therapeutics 4:4, pages 403-410.
Crossref
Crossref
C. H. Wilder-Smith, T. Ernst, M. Gennoni, B. Zeyen, F. Halter & H. S. Merki. (1990) Tolerance to oral H2-receptor antagonists. Digestive Diseases and Sciences 35:8, pages 976-983.
Crossref
Crossref
G. Coruzzi & G. Bertaccini. (1989) Increased parietal cell sensitivity after chronic treatment with ranitidine in the conscious cat. Agents and Actions 28:3-4, pages 215-217.
Crossref
Crossref
I.N. Marks, Gerardine O. Young, Nel A. Tigler-Wybrandi, Sharon Bridger & Keith A. Newton. (1989) Acid-secretory response and parietal cell sensitivity in patients with duodenal ulcer before and after treatment with sucralfate or ranitidine. The American Journal of Medicine 86:6, pages 145-147.
Crossref
Crossref
Shui Kum Lam. (1989) Implications of sucralfate-induced ulcer healing and relapse. The American Journal of Medicine 86:6, pages 122-126.
Crossref
Crossref
I N Marks. (1989) Alteration of H2 receptor sensitivity in duodenal ulcer patients.. Gut 30:5, pages 701-703.
Crossref
Crossref
G M Fullarton, G McLauchlan, A Macdonald, G P Crean & K E McColl. (1989) Rebound nocturnal hypersecretion after four weeks treatment with an H2 receptor antagonist.. Gut 30:4, pages 449-454.
Crossref
Crossref
Stephen G. Chiverton & Richard H. Hunt. (1989) Initial Therapy and Relapse of Duodenal Ulcer: Possible Acid Secretory Mechanisms. Gastroenterology 96:2, pages 632-639.
Crossref
Crossref
I.N. Marks. (1988) Site-protective agents. Baillière's Clinical Gastroenterology 2:3, pages 609-620.
Crossref
Crossref
G. M. FULLARTON, G. LAFERLA, G. P. CREAN & K. E. L. McCOLL. (2007) A comparison of the effects of treatment with either famotidine 40 mg or cimetidine 800 mg nocte on gastric acid secretion and serum gastrin. Alimentary Pharmacology & Therapeutics 2:2, pages 161-166.
Crossref
Crossref
G Dobrilla, P Vallaperta & S Amplatz. (1988) Influence of ulcer healing agents on ulcer relapse after discontinuation of acute treatment: a pooled estimate of controlled clinical trials.. Gut 29:2, pages 181-187.
Crossref
Crossref
RichardH. Hunt. (1987) PROSTAGLANDINS FOR PEPTIC ULCER DISEASE. The Lancet 329:8544, pages 1262.
Crossref
Crossref
J P Miller & E B Faragher. (1986) Relapse of duodenal ulcer: does it matter which drug is used in initial treatment?. BMJ 293:6555, pages 1117-1118.
Crossref
Crossref